Actinium Pharmaceuticals (ATNM) Cash from Operations (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Cash from Operations for 8 consecutive years, with 2741000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations changed N/A to 2741000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 24780000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at 24580000.0 for FY2025, 25.68% up from the prior year.
  • Cash from Operations for Q4 2025 was 2741000.0 at Actinium Pharmaceuticals, up from 7574000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 27918000.0 in Q2 2022, with the low at 15077000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 5394764.71, with a median of 7374000.0 recorded in 2024.
  • The sharpest move saw Cash from Operations soared 709.03% in 2022, then crashed 160.8% in 2023.
  • Over 5 years, Cash from Operations stood at 5052000.0 in 2021, then crashed by 53.96% to 7778000.0 in 2022, then grew by 3.7% to 7490000.0 in 2023, then tumbled by 59.88% to 11975000.0 in 2024, then soared by 122.89% to 2741000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 2741000.0, 7574000.0, and 11975000.0 for Q4 2025, Q1 2025, and Q3 2024 respectively.